Skip to main content
SGLT2 inhibitors tied to reduced CVD risk in diabetes

A study in the Journal of the American Heart Association found that sodium-glucose cotransporter 2 inhibitors could help protect against major adverse cardiac events like heart failure and cardiovascular death, as well as death from any cause, among individuals with type 2 diabetes. Researchers evaluated data from 38,723 patients with type 2 diabetes and wrote that "SGLT2 inhibition should be considered in all patients with type 2 diabetes mellitus and elevated risk of cardiovascular disease, even in the absence of established disease."

Full Story: